세계의 강압제 시장 : 예측(2025-2030년)

The global anti-hypertensive drug market is estimated to grow at a CAGR of 2.88% to reach a market size of US$47.241 billion in 2030 from US$41.082 billion in 2025.

The global anti-hypertensive drug market is expected to experience significant growth over the next five years, driven by the increasing prevalence of hypertension linked to unhealthy lifestyles. Additionally, the growing geriatric population is a major factor contributing to the rising demand for these medications, as older adults are more prone to high blood pressure compared to younger individuals. Hypertension is a leading cause of premature deaths worldwide.Several factors contribute to the rise in high blood pressure, including excessive smoking, chronic stress, chronic kidney disease, high alcohol consumption, and obesity. The increasing number of smokers and alcohol consumers, particularly among millennials, is projected to create substantial growth opportunities for the market as hypertension rates are expected to rise due to these lifestyle choices. Furthermore, the growing obesity rates among adults will likely drive demand for anti-hypertensive drugs in the coming years.Rapid urbanization and globalization are also deteriorating public health conditions. Changing lifestyles, increased stress levels, and unhealthy eating and sleeping habits contribute to higher blood pressure, which is anticipated to positively influence the growth of the anti-hypertensive drug market over the next five years.

Key Drivers of the Global Anti-Hypertensive Drug Market

• Rising Prevalence of Hypertension: The increasing incidence of hypertension is a primary driver for the anti-hypertensive drug market. The growing number of smokers and individuals with excessive alcohol consumption-especially in developing economies-significantly boosts demand for these medications. According to the World Health Organization (WHO), approximately 1.13 billion people worldwide suffer from hypertension, with a majority residing in low- and middle-income countries. WHO's goal to reduce hypertension prevalence by 25% by 2025 is also expected to enhance demand for these drugs.
• Public Health Challenge: The necessity of these medications is underscored by their role in addressing a major public health challenge. Hypertension significantly increases the risk of cardiovascular diseases; thus, controlling elevated blood pressure levels can help reduce the risks of strokes, heart attacks, and heart failures.

Geographical Outlook

• Asia Pacific: The global anti-hypertensive drug market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia Pacific. The Asia Pacific region is projected to witness notable growth due to rising hypertension rates in developing countries like India and China, driven by high smoking rates and unhealthy lifestyles. Additionally, an increasing geriatric population in many APAC nations supports market growth.
• North America: This region is expected to maintain a significant share of the anti-hypertensive drug market due to lifestyle factors such as obesity and physical inactivity contributing to hypertension. The aging population makes individuals more susceptible to developing high blood pressure. North America's advanced healthcare system provides opportunities for effective treatment through innovative medical technologies. The presence of leading pharmaceutical companies developing or marketing anti-hypertensive drugs further fuels market growth in this region. Increased awareness about hypertension risks and the availability of new potent medications will also contribute positively to market expansion.

In summary, the global anti-hypertensive drug market is set for substantial growth driven by rising hypertension prevalence and an aging population. Geographically, both Asia Pacific and North America are expected to play crucial roles in this expansion due to distinct socio-economic factors influencing health outcomes.

Reasons for buying this report:-

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Market Segmentation:

The global anti-hypertensive drug market is segmented and analyzed as below:

By Drug Class

• Diuretics
• Beta-Blockers
• ACI Inhibitors
• Calcium Channel Blockers
• Combined Alpha and Beta-Blockers
• Others

By Type

• Primary Hypertension
• Secondary Hypertension

By Sales Channel

• Prescription
• Over-the-counter (OTC)

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• France
• United Kingdom
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• Israel
• Others
• Asia Pacific
• China
• Japan
• South Korea
• India
• Indonesia
• Taiwan
• Others

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Process

3. EXECUTIVE SUMMARY

• 3.1. Key Findings
• 3.2. Analyst View

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY DRUG CLASS

• 5.1. Introduction
• 5.2. Diuretics
• 5.3. Beta-Blockers
• 5.4. ACI Inhibitors
• 5.5. Calcium Channel Blockers
• 5.6. Combined Alpha and Beta-Blockers
• 5.7. Others

6. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY TYPE

• 6.1. Introduction
• 6.2. Primary Hypertension
• 6.3. Secondary Hypertension

7. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY SALES CHANNEL

• 7.1. Introduction
• 7.2. Prescription
• 7.3. Over-the-counter (OTC)

8. GLOBAL ANTI-HYPERTENSIVE DRUG MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Drug Class
  • 8.2.2. By Type
  • 8.2.3. By Sales Channel
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Drug Class
  • 8.3.2. By Type
  • 8.3.3. By Sales Channel
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Drug Class
  • 8.4.2. By Type
  • 8.4.3. By Sales Channel
  • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. United Kingdom
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Drug Class
  • 8.5.2. By Type
  • 8.5.3. By Sales Channel
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. Israel
    • 8.5.4.3. Others
• 8.6. Asia Pacific
  • 8.6.1. By Drug Class
  • 8.6.2. By Type
  • 8.6.3. By Sales Channel
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. Japan
    • 8.6.4.3. South Korea
    • 8.6.4.4. India
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Taiwan
    • 8.6.4.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Boehringer Ingelheim International GmbH
• 10.2. DAIICHI SANKYO COMPANY, LIMITED
• 10.3. Novartis AG
• 10.4. Pfizer Inc.
• 10.5. Johnson & Johnson
• 10.6. Merck and Co. Inc.
• 10.7. Lupin Pharmaceuticals, Inc.
• 10.8. Sanofi S.A.
• 10.9. Sun Pharmaceutical Industries Ltd.
• 10.10. Bristol-Myers Squibb and Company